Skip to search formSkip to main contentSkip to account menu

ranolazine

Known as: Renolazine, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)-, Ranolazine [Chemical/Ingredient] 
An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti… 
National Institutes of Health

Related topics

Related topics

17 relations
12 HR ranolazine 500 MG Extended Release Oral Tablet [Ranexa]Angina PectorisAntianginalsIn Blood

Broader (2)

Cardiovascular AgentsSodium Channel Blockers

Narrower (3)

RS 43285RS 43285-193Ranexa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function
Background Treatments for patients with myocardial ischemia in the absence of angiographic obstructive coronary artery disease… 
2017
2017
CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived…
Highly Cited
2011
Highly Cited
2011
Ranolazine for the Treatment of Heart Failure With Preserved Ejection Fraction: Background, Aims, and Design of the RALI‐DHF Study
Heart failure with preserved ejection fraction (HFpEF), formerly referred to as diastolic heart failure (DHF), accounts for >50… 
2010
2010
Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability
BackgroundA direct role of sodium channels in pain has recently been confirmed by establishing a monogenic link between SCN9A… 
Highly Cited
2008
Highly Cited
2008
State- and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by Ranolazine
Ranolazine is an antianginal agent that targets a number of ion channels in the heart, including cardiac voltage-gated Na… 
2008
2008
Ranolazine Inhibits An Oxidative Stress-induced Increase in Myocyte Sodium and Calcium Loading During Simulated-demand Ischemia
Ranolazine inhibits the late Na+ current and is proposed to reduce angina by decreasing [Na+]i during ischemia, thereby reducing… 
Review
2007
Review
2007
Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: considerations for diagnosis and treatment.
2005
2005
Effect of Hepatic Impairment on the Multiple‐Dose Pharmacokinetics of Ranolazine Sustained‐Release Tablets
The effect of hepatic impairment on the pharmacokinetics of a sustained‐release formulation of ranolazine and 3 major metabolites… 
Highly Cited
2001
Highly Cited
2001
Evidence that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular system
Abstract. The clinical anti-anginal effectiveness of ranolazine is currently being evaluated. However, the mechanism of its anti… 
1993
1993
Modulation of α1-Adrenoceptors in Rat Left Ventricle by Ischaemia and Acyl Carnitines: Protection by Ranolazine
Myocardial α1-adrenoceptor number has been reported to increase during ischaemia in myocytes consequent to an increase in acyl… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)